Belfast-based medtech firm Diaceutics has launched its new global diagnostic network for precision medicine to streamline global cancer test development.
Cancer testing has come a long way in recent years thanks to advances in precision medicine, but new tests and treatments developed each year across the global pharma industry can follow different standards and will take a long time to pass regulatory steps before they can be rolled out.
Belfast-based MedTech firm Diaceutics has now launched a new digital platform in an effort to bring stakeholders together from across the pharma industry to collaborate on testing issues in a standardised way. The complany has announced that its new platform DXRX – The Diagnostic Network®, is the world’s first diagnostic network for precision medicine, and will solve issues with today's broken cancer testing ecosystem.
RELATED: Diaceutics raises further £4m from Silicon Valley Bank to support global growth
Two global pharma companies have been piloting the platform along with 38 laboratories and diagnostic companies around the world. The platform "provides access to a pipeline of global diagnostic testing data on one secure platform," to monitor test quality at a local level, and to pull in an expert advisory panel on everything from cancer research and molecular diagnostics to telemedicine and FDA approval.
The platform also helps clients outsource diagnostic development and commercialisation in order to reduce the time to market for new therapies. Diaceutics believes that the new platform will shorten the time it takes for new tests and therapies to be developed and widely adopted from years to just months, with promising early collaborations current running in the US, EU, and Asia.
RELATED: Belfast medtech Diaceutics named IPO of the Year 2020
Head of Global Marketing at Diaceutics, Sarah Colgan said: "The fact that it can take years for a biomarker test to reach optimal adoption – as is the case with PD-L1 today – is unacceptable for patients. We believe that DXRX sets a new industry standard for precision medicine which, until today, has been reliant upon a business model entirely unfit for purpose. There is a better way to get every patient the treatment they deserve. We believe that DXRX is that way."
For more information, head over to www.diaceutics.com
Source: Written based on press release
